<DOC>
	<DOCNO>NCT02611674</DOCNO>
	<brief_summary>The primary objective study estimate rank-order longitudinal standardize mean change 6 month 12 month , set novel outcome measure administer participant amyotrophic lateral sclerosis ( ALS ) , order identify measure sensitive disease progression Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised ( ALSFRS-R ) . The secondary objective study : To evaluate test-retest reproducibility outcome measure ; To determine correlation 6 12-month change exploratory measure 18 24-month change ALSFRS-R survival ; To assess correlation between/among various measure ; To obtain biological sample order identify molecular correlate clinical measure characterize previously identify novel molecular biomarkers disease progression incorporation future clinical study .</brief_summary>
	<brief_title>Methodology Study Novel Outcome Measures Assess Progression ALS</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Key A diagnosis sporadic familial ALS ALS onset within â‰¤5 year Must 16 85 year age , inclusive , site United States 18 85 year age , inclusive , site outside United States Key History positive test result Screening human immunodeficiency virus ( HIV ) History positive test result Screening hepatitis C virus ( HCV ) antibody hepatitis B virus ( HBV ) Possibility neuromuscular weakness ALS Unspecified reason , opinion site Investigator , make subject unsuitable enrollment unlikely able complete , minimum , Month 6 Visit NOTE : Other protocol define Inclusion/ Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>